CN109030830A - Adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit - Google Patents
Adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit Download PDFInfo
- Publication number
- CN109030830A CN109030830A CN201810730559.8A CN201810730559A CN109030830A CN 109030830 A CN109030830 A CN 109030830A CN 201810730559 A CN201810730559 A CN 201810730559A CN 109030830 A CN109030830 A CN 109030830A
- Authority
- CN
- China
- Prior art keywords
- serum
- haemophilus parasuis
- protein
- adhesin
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000606807 Glaesserella parasuis Species 0.000 title claims abstract description 96
- 238000002965 ELISA Methods 0.000 title claims abstract description 58
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 title claims abstract description 49
- 238000003149 assay kit Methods 0.000 title abstract description 4
- 101710153593 Albumin A Proteins 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000012360 testing method Methods 0.000 claims abstract description 16
- 210000002966 serum Anatomy 0.000 claims description 122
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 238000001514 detection method Methods 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 42
- 239000011248 coating agent Substances 0.000 claims description 38
- 238000000576 coating method Methods 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000005406 washing Methods 0.000 claims description 25
- 239000013642 negative control Substances 0.000 claims description 24
- 239000008367 deionised water Substances 0.000 claims description 23
- 229910021641 deionized water Inorganic materials 0.000 claims description 23
- 230000003053 immunization Effects 0.000 claims description 22
- 239000013641 positive control Substances 0.000 claims description 21
- 239000003085 diluting agent Substances 0.000 claims description 20
- 238000002649 immunization Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 238000007865 diluting Methods 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000012089 stop solution Substances 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 235000020183 skimmed milk Nutrition 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 abstract description 16
- 208000015181 infectious disease Diseases 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 8
- 230000014509 gene expression Effects 0.000 abstract description 8
- 244000052616 bacterial pathogen Species 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 3
- 108010022355 Fibroins Proteins 0.000 abstract 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 102000057593 human F8 Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940047431 recombinate Drugs 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 37
- 241000282887 Suidae Species 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 108010054473 Bacteria oligopeptide permease Proteins 0.000 description 5
- 101710116435 Outer membrane protein Proteins 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 3
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- 241000194021 Streptococcus suis Species 0.000 description 3
- AQAMPXBRJJWPNI-JHEQGTHGSA-N Thr-Gly-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AQAMPXBRJJWPNI-JHEQGTHGSA-N 0.000 description 3
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229940051027 pasteurella multocida Drugs 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 description 2
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 2
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000588779 Bordetella bronchiseptica Species 0.000 description 2
- 101100030139 Chlamydia pneumoniae pmp10 gene Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 2
- 101100428373 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POR1 gene Proteins 0.000 description 2
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229910001453 nickel ion Inorganic materials 0.000 description 2
- 101150087557 omcB gene Proteins 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- SFNFGFDRYJKZKN-XQXXSGGOSA-N Ala-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O SFNFGFDRYJKZKN-XQXXSGGOSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- OTCJMMRQBVDQRK-DCAQKATOSA-N Arg-Asp-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OTCJMMRQBVDQRK-DCAQKATOSA-N 0.000 description 1
- JJIBHAOBNIFUEL-SRVKXCTJSA-N Arg-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)N JJIBHAOBNIFUEL-SRVKXCTJSA-N 0.000 description 1
- NXVGBGZQQFDUTM-XVYDVKMFSA-N Asn-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N NXVGBGZQQFDUTM-XVYDVKMFSA-N 0.000 description 1
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 description 1
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 1
- KSBHCUSPLWRVEK-ZLUOBGJFSA-N Asn-Asn-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KSBHCUSPLWRVEK-ZLUOBGJFSA-N 0.000 description 1
- IOTKDTZEEBZNCM-UGYAYLCHSA-N Asn-Asn-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOTKDTZEEBZNCM-UGYAYLCHSA-N 0.000 description 1
- FAEFJTCTNZTPHX-ACZMJKKPSA-N Asn-Gln-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FAEFJTCTNZTPHX-ACZMJKKPSA-N 0.000 description 1
- KUYKVGODHGHFDI-ACZMJKKPSA-N Asn-Gln-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O KUYKVGODHGHFDI-ACZMJKKPSA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 1
- PTSDPWIHOYMRGR-UGYAYLCHSA-N Asn-Ile-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O PTSDPWIHOYMRGR-UGYAYLCHSA-N 0.000 description 1
- ANPFQTJEPONRPL-UGYAYLCHSA-N Asn-Ile-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O ANPFQTJEPONRPL-UGYAYLCHSA-N 0.000 description 1
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 description 1
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 1
- OOXUBGLNDRGOKT-FXQIFTODSA-N Asn-Ser-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OOXUBGLNDRGOKT-FXQIFTODSA-N 0.000 description 1
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 1
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- FRSGNOZCTWDVFZ-ACZMJKKPSA-N Asp-Asp-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRSGNOZCTWDVFZ-ACZMJKKPSA-N 0.000 description 1
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 1
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 1
- QOCFFCUFZGDHTP-NUMRIWBASA-N Asp-Thr-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOCFFCUFZGDHTP-NUMRIWBASA-N 0.000 description 1
- KBJVTFWQWXCYCQ-IUKAMOBKSA-N Asp-Thr-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KBJVTFWQWXCYCQ-IUKAMOBKSA-N 0.000 description 1
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 1
- RSMZEHCMIOKNMW-GSSVUCPTSA-N Asp-Thr-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RSMZEHCMIOKNMW-GSSVUCPTSA-N 0.000 description 1
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000283899 Gazella Species 0.000 description 1
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
- LLRJEFPKIIBGJP-DCAQKATOSA-N Gln-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N LLRJEFPKIIBGJP-DCAQKATOSA-N 0.000 description 1
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 1
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 1
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 1
- VAZZOGXDUQSVQF-NUMRIWBASA-N Glu-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)O VAZZOGXDUQSVQF-NUMRIWBASA-N 0.000 description 1
- PCBBLFVHTYNQGG-LAEOZQHASA-N Glu-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N PCBBLFVHTYNQGG-LAEOZQHASA-N 0.000 description 1
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 1
- HJIFPJUEOGZWRI-GUBZILKMSA-N Glu-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N HJIFPJUEOGZWRI-GUBZILKMSA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 1
- RFDHKPSHTXZKLL-IHRRRGAJSA-N Glu-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N RFDHKPSHTXZKLL-IHRRRGAJSA-N 0.000 description 1
- VFZIDQZAEBORGY-GLLZPBPUSA-N Glu-Gln-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VFZIDQZAEBORGY-GLLZPBPUSA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- XMPAXPSENRSOSV-RYUDHWBXSA-N Glu-Gly-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XMPAXPSENRSOSV-RYUDHWBXSA-N 0.000 description 1
- XOFYVODYSNKPDK-AVGNSLFASA-N Glu-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XOFYVODYSNKPDK-AVGNSLFASA-N 0.000 description 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- CAQXJMUDOLSBPF-SUSMZKCASA-N Glu-Thr-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAQXJMUDOLSBPF-SUSMZKCASA-N 0.000 description 1
- DWUKOTKSTDWGAE-BQBZGAKWSA-N Gly-Asn-Arg Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DWUKOTKSTDWGAE-BQBZGAKWSA-N 0.000 description 1
- BGVYNAQWHSTTSP-BYULHYEWSA-N Gly-Asn-Ile Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BGVYNAQWHSTTSP-BYULHYEWSA-N 0.000 description 1
- JMQFHZWESBGPFC-WDSKDSINSA-N Gly-Gln-Asp Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JMQFHZWESBGPFC-WDSKDSINSA-N 0.000 description 1
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 1
- DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 1
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- LYSVCKOXIDKEEL-SRVKXCTJSA-N His-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 LYSVCKOXIDKEEL-SRVKXCTJSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- ZZHGKECPZXPXJF-PCBIJLKTSA-N Ile-Asn-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZZHGKECPZXPXJF-PCBIJLKTSA-N 0.000 description 1
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 1
- URWXDJAEEGBADB-TUBUOCAGSA-N Ile-His-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N URWXDJAEEGBADB-TUBUOCAGSA-N 0.000 description 1
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 1
- SAVXZJYTTQQQDD-QEWYBTABSA-N Ile-Phe-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SAVXZJYTTQQQDD-QEWYBTABSA-N 0.000 description 1
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 1
- KBDIBHQICWDGDL-PPCPHDFISA-N Ile-Thr-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N KBDIBHQICWDGDL-PPCPHDFISA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- WXJKFRMKJORORD-DCAQKATOSA-N Lys-Arg-Ala Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCCCN WXJKFRMKJORORD-DCAQKATOSA-N 0.000 description 1
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- XMMWDTUFTZMQFD-GMOBBJLQSA-N Met-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC XMMWDTUFTZMQFD-GMOBBJLQSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000606752 Pasteurellaceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 1
- OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- QUBVFEANYYWBTM-VEVYYDQMSA-N Pro-Thr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUBVFEANYYWBTM-VEVYYDQMSA-N 0.000 description 1
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 1
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 1
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
- YQQKYAZABFEYAF-FXQIFTODSA-N Ser-Glu-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQQKYAZABFEYAF-FXQIFTODSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 1
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- UUSQVWOVUYMLJA-PPCPHDFISA-N Thr-Lys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UUSQVWOVUYMLJA-PPCPHDFISA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- YRJOLUDFVAUXLI-GSSVUCPTSA-N Thr-Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O YRJOLUDFVAUXLI-GSSVUCPTSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- FJBCEFPCVPHPPM-STECZYCISA-N Tyr-Ile-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O FJBCEFPCVPHPPM-STECZYCISA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 1
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- PDDJTOSAVNRJRH-UNQGMJICSA-N Val-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](C(C)C)N)O PDDJTOSAVNRJRH-UNQGMJICSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/285—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit.The invention demonstrates that adhesin albumin A pd is located at the outer membrane of haemophilus parasuis, there is expression in known 15 serotype, but in the not no albumen of other bacterial pathogens of pig, uses it that there is high sensibility and specificity as diagnostic antigen.Optimum combination sticks the method for expression and the purifying of fibroin, obtains immunogenicity and the good recombinant protein of reactionogenicity.Optimize the component and dosage, reaction condition, result judgement standard to recombinate the indirect ELISA method for sticking fibroin as envelope antigen, is prepared for the indirect ELISA antibody assay kit of haemophilus parasuis.Animal experiment confirms the antibody test that the kit can be used for after haemophilus parasuis vaccine immunity and bacterium infection.In the Synthetical prevention and seroepidemiological survey of Haemophilus parasuis, which will have broad application prospects.
Description
Technical Field
The invention relates to the fields of biotechnology and animal infectious diseases, in particular to an adhesin protein Apd and application thereof in preparation of an indirect ELISA antibody detection kit for haemophilus parasuis.
Background
Haemophilus Parasuis (HPS) is a common bacterium of the upper respiratory tract of pigs, belongs to the family Pasteurellaceae, the genus Haemophilus, and is a fine spherical, coccobate-to-filamentous gram-negative bacterium. HPS can cause haemophilus parasuis (also called Gratherse disease) in pigs when the immunity of the pigs is low or the pigs are stressed. Acute infection with HPS can lead to multiple serositis, arthritis and meningitis, septicemia and death; chronic infection can cause suppurative rhinotracheitis and pneumonia. HPS is often co-infected with E.coli, S.suis, and Pasteurella multocida, complicating the disease. The disease occurs and is prevalent in countries and regions of the world where pigs are raised, and can result in 30% mortality in weaned piglets. Because the immunosuppressive diseases of pigs in China are multiple, the occurrence and prevalence of haemophilus parasuis are particularly serious. A specific and sensitive antibody detection method is indispensable in serological diagnosis of haemophilus parasuis, antibody monitoring after vaccine immunization and serum epidemiological investigation.
Antibody detection methods for bacterial pathogens are often difficult to establish, especially for HPS with 15 serotypes and 27% of untypible strains (Oliveira et al, 2003). The plate agglutination test is simple and easy to implement, and can use thallus suspension as agglutination antigen, but the method has low specificity and sensitivity and is limited by the serum type of the agglutination antigen, namely, the specific serotype antigen can only detect the corresponding serotype antibody. The indirect ELISA is carried out by taking thalli as a coating antigen, and because the structure and the composition of bacteria are complex and the types and the quantity of antigens are large, the coating antigen usually has cross reaction with antibodies of similar components of other bacteria in detected serum, thereby causing false positive.
Early methods for detection of HPS antibodies were complement fixation assays, indirect hemagglutination assays and ELISA (Oliveira et al, 2004). The complement fixation test requires sheep red blood cells and guinea pig complement, and these materials are not readily available and prepared in a timely manner, and are cumbersome to perform and are rarely used today. There are two kinds of antigens, namely, an antigen for indirect hemagglutination and an antigen for ELISA, and the supernatant (polysaccharide and protein) after bacterial ultrasonication or LPS extracted by a hot phenol water method. The indirect hemagglutination and ELISA antibody detection methods established with these two antigen components are not only unstable, but also prone to false negatives, as well as detection of immunoprotected porcine sera (Oliveira et al, 2004).
In recent years, there has been established an antibody detection method for HPS indirect ELISA using, as a diagnostic antigen, a protein expressed by escherichia coli, such as HPS oligopeptide permease (OppA) (plantarenaline et al, 2015), cytoswelling lethal toxin (CDT) (liushuanghong, 2016) and outer membrane protein (OMP2, OMP5) (gazelle et al, 2011). In the domestic market, an indirect ELISA antibody detection kit for haemophilus parasuis of BioChek company, Netherlands, takes oligopeptide permease (OppA) as a diagnostic antigen. However, because the oligopeptide permease gene is highly conserved in HPS, E.coli, Salmonella typhi and Pasteurella multocida (98% nucleotide identity), the cytodistending lethal toxin has structurally and functionally similar homologous proteins in E.coli (44% amino acid identity), while the outer membrane proteins OMP2, OMP5 also have homologous proteins in A. pleuropneumoniae (42% and 71% amino acid identity). Such antibody detection methods or kits inevitably cross-react with pathogens having similar antigenic components, resulting in false positives.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides an adhesin protein (Aida passagermain, Apd) and application thereof in preparation of a haemophilus parasuis ELISA antibody detection kit. Since the adhesin protein Apd is a protein specific to haemophilus parasuis, it is not present in other relevant bacterial pathogens in pigs. The mouse immune test and immunoblotting confirm that the recombinant Apd protein has good immunogenicity and reactivity. Moreover, the recombinant Apd protein was reactive with antisera from 13 serotype strains, which were reactive with 15 serotype bacteria, indicating that Apd as a diagnostic antigen was not restricted to serotype differences. The haemophilus parasuis ELISA antibody detection kit using the recombinant Apd protein as a coating antigen can detect the antibody from the pig serum immunized by the haemophilus parasuis inactivated vaccine and infected by live bacteria, and the positive rate of the antibody is related to the toxic attack protection rate of pigs. The kit has wide application prospect in serological diagnosis of haemophilus parasuis, evaluation of vaccine immunity effect and seroepidemiological investigation.
To achieve the above object, the present invention provides an adhesin protein Apd, which has an amino acid sequence characterized by:
(1) a protein consisting of an amino acid sequence shown in SEQ ID No. 2; or
(2) An amino acid sequence which has 90-100% homology with the amino acid sequence defined by the sequence SEQ ID No.2 and encodes the protein with the same function; or
(3) Protein which is derived from the protein (1) and has the same activity and is obtained by adding, deleting or replacing one or more amino acids in the amino acid sequence shown in SEQ ID No. 2;
the nucleotide sequence of the gene apd for coding the adhesin is shown as SEQ ID No. 1.
The invention also provides a primer pair for obtaining the adhesin gene apd, which comprises the following components in parts by weight:
P1,5’-CGGAATTC(EcoRI)GGAAACTTATATTGTTACTGGTGAA-3’,
P2,5’-CCCTCGAG(XhoI)GGTGATTGTGATTTTATTGTGGT-3’。
the present invention also provides a recombinant plasmid pET-Apd, wherein the recombinant expression vector is an expression vector containing the adhesin gene apd of claim 3, and the expression vector is pET-25 b.
The invention also provides a host cell of the recombinant expression vector, and the host cell is escherichia coli BL21(DE 3).
The invention also provides a preparation method of the recombinant adhesin protein Apd, which comprises the following steps: comprises the following steps:
(1) culturing escherichia coli competent cells BL21(DE3) containing recombinant plasmid pET-Apd overnight, centrifuging culture bacterial liquid, and resuspending a precipitate by using a buffer solution to obtain suspension bacterial liquid;
(2) and (3) carrying out thallus crushing on the suspension liquid at a low temperature, centrifugally collecting a supernatant, and purifying the supernatant to obtain the recombinant adhesin protein rApd.
The invention also provides an indirect ELISA antibody detection kit for haemophilus parasuis, which comprises an adhesin-coated ELISA plate, a sample diluent, negative and positive control serum, 20-time concentrated washing liquid, an enzyme-labeled secondary antibody, a developing liquid A, a developing liquid B and a stop solution;
the preparation of the adhesin protein coated ELISA plate comprises the following steps: the preparation method comprises the following steps: purified rApd protein was used as the coating antigen, rApd was diluted to 0.5. mu.g/mL with carbonate buffer, coated overnight at 4 ℃ and blocked with 0.05g/mL skim milk in PBS buffer (pH7.4) for 2h at 37 ℃.
The sample diluent is: 50mL of PBS buffer solution (pH7.4), 0.25g of bovine serum albumin and 0.5 μ L of Tween-2025;
the positive control serum: the preparation method comprises the following steps: immunizing 1-month-old healthy piglet with Haemophilus parasuis twice, collecting blood serum two weeks after two-time immunization, and detecting OD630Taking 4 parts of serum with the value of 1.00-1.20, mixing, and diluting with a sample diluent at a ratio of 1:200 to serve as positive control serum;
the negative control serum: detecting OD of healthy pig serum raised under the same condition during positive control serum preparation630Mixing 4 parts of serum with a value of 0.15-0.25, and diluting with sample diluent at a ratio of 1:200 to obtain negative control serum;
the 20-fold concentrated washing solution: 160.00g of NaCl, 4.00g of KCl and Na2HPO4·12H2O 72.60g,KH2PO44.80g of the extract is dissolved in 900mL of deionized water, the pH value is adjusted to 7.4 by concentrated hydrochloric acid, 10mL of Tween-20 is added, the volume is fixed to 1L, and the extract is filtered, sterilized and stored at room temperature;
the enzyme-labeled secondary antibody: horse radish peroxidase-labeled goat anti-pig secondary antibody purchased from Wuhan Ante & Tejie biotechnology Limited (imported subpackaging) and diluted by sample diluent at a ratio of 1: 15000;
the color developing liquid A: na (Na)2HPO4·12H2Adding 800ml of deionized water into 14.60g of O, 9.33g of citric acid and 2ml of 30% hydrogen peroxide for dissolving, adjusting the pH value to 5.0-5.4, and setting the volume to 1000 ml;
the color developing liquid B: 0.02g of Tetramethylbenzidine (TMB) and 10.00ml of absolute ethyl alcohol, adding deionized water for dissolving and fixing the volume to 1000 ml; the stop solution is as follows: to 10mL of deionized water was added 25. mu.L of hydrofluoric acid.
The method for detecting the haemophilus parasuis antibody by using the kit comprises the following steps:
(1) diluting the serum to be detected by sample diluent at a ratio of 1:200, adding 100 mu L of each sample into an enzyme label plate, and simultaneously adding 100 mu L of negative and positive control serum into the enzyme label plate; performing incubator at 37 deg.C for 45min, diluting 20 times of concentrated washing solution with deionized water at a ratio of 1:19, adding 200 μ L per well, standing for 5min, discarding, drying, and washing for 3 times;
(2) adding 100 μ L of enzyme-labeled secondary antibody into each well, reacting at 37 deg.C for 30min, discarding, adding 200 μ L of washing solution into each well, standing for 5min, discarding, drying, and washing for 3 times;
(3) adding 50 mu L of substrate solution A into each hole, adding 50 mu L of substrate solution B, uniformly mixing, keeping out of the sun at room temperature for 15min, developing, adding 50 mu L of stop solution, and measuring the OD value with the wavelength of 630nm on an enzyme-linked immunosorbent assay instrument within 10 min;
(4) and (4) judging a result: when the S/N of the serum to be detected is more than or equal to 2.60, the serum is judged to be positive; S/N<2.6, the result is judged to be negative. S represents the OD of the serum to be tested630Value, N represents the negative control serum OD630Value, the condition for the test to be established is the negative and positive control serum OD630The difference value is more than or equal to 0.5, wherein the serum of the pig to be detected: porcine venous blood serum was isolated.
The invention has the beneficial effects that:
the adhesion protein disclosed by the invention is specific to haemophilus parasuis, and the antibody detection kit disclosed by the invention can be used for detecting antibodies after haemophilus parasuis vaccine immunization or pathogen infection, does not have cross reaction with other related bacterial pathogens, and is not limited by different serotypes of haemophilus parasuis.
Drawings
FIG. 1 is a diagram showing the detection of E.coli expression of three recombinant proteins;
FIG. 2 is a diagram of the purification of three recombinant proteins;
FIG. 3 is a result chart of three recombinant proteins for detecting Haemophilus parasuis negative and positive serum;
FIG. 4 is a graph showing the immunogenicity of recombinant adhesin proteins;
FIG. 5 is a map of the localization of adhesin protein in Haemophilus parasuis;
FIG. 6 is a graph showing the serum titer of mice immunized with recombinant adhesin protein;
FIG. 7 is a graph showing the results of detection of 15 serological Haemophilus parasuis by Western blot using recombinant adhesin protein antiserum;
FIG. 8 is a graph showing the results of detection of recombinant adhesin protein by Western blot using 15 serotype Haemophilus parasuis antiserums;
FIG. 9 is a result chart of detection of negative and positive sera after optimization of ELISA reaction conditions;
FIG. 10 is a graph showing the results of negative and positive serum detection of the supernatant after the disruption of Haemophilus parasuis;
FIG. 11 is a graph showing the results of detection of positive and negative serum by Haemophilus parasuis;
FIG. 12 is a graph showing the results of the kit for detecting the sera of pigs after vaccine immunization and bacterial infection;
FIG. 13 is a result diagram of the antibody growth and death law of the kit after detecting vaccine immunity and bacterial infection.
Detailed Description
The invention is described in further detail below with reference to the figures and specific embodiments for the understanding of those skilled in the art.
EXAMPLE 1 Synthesis or cloning of the adhesin Gene apd
(1) Synthesis of adhesin Gene apd
The gene apd is synthesized according to the nucleotide sequence shown as SEQ ID No. 1.
(2) Cloning of the adhesin Gene apd
Primer pairs were designed with the genome of haemophilus parasuis isolate CF7066 (held by the dawn teacher, university of china agriculture):
P1,5’-CGGAATTC(EcoRI)GGAAACTTATATTGTTACTGGTGAA-3’,
P2,5’-CCCTCGAG(Xho I)GGTGATTGTGATTTTATTGTGGT- 3’;
taking a haemophilus parasuis isolate CF7066 genome as a template to carry out PCR amplification, wherein a PCR system comprises the following steps: 31.5. mu.L of deionized water, 5. mu.L of 10 XProbest Buffer II, 4. mu.L of dNTP mix (2.5mM), 2. mu. L P1 (10. mu.M/L), 2. mu. L P2 (10. mu.M/L), 0.5. mu.L of Pyrobest DNA Polymerase (Takara), 5. mu.L of Haemophilus parasuis genomic DNA (150 ng/. mu.L); PCR reaction procedure: pre-denaturation at 94 ℃ for 5min, cycling, denaturation at 94 ℃ for 30s, renaturation at 60 ℃ for 30s, extension at 72 ℃ for 90s, 30 cycles, extension at 72 ℃ for 10min, and storing at 4 ℃ to obtain a PCR product; sequencing the PCR product, wherein the nucleotide sequence of the PCR product is shown as SEQ ID No.1, and the PCR product is named as 'gene apd'.
EXAMPLE 2 preparation of adhesin proteins
(1) Obtaining of adhesin Gene
The invention obtains DNA fragment of 1577 nucleotides by DNA synthesis; or a 1577bp DNA fragment was amplified from the Haemophilus parasuis isolate CF7066 by the PCR primers, system and reaction procedure described in example 1. The DNA fragment is named as apd, and the nucleotide sequence of the DNA fragment is shown as SEQ ID No. 1.
(2) Construction of adhesin expression plasmid
dissolving the synthesized DNA fragment with deionized water, or recovering PCR amplified fragment, double enzyme cutting the DNA fragment and the vector pET-25b (Novagen) with EcoR I and Xho I, recovering the enzyme cutting product and connecting the vector, transforming the connecting product into Escherichia coli DH5 α, culturing overnight at 37 ℃ until a single colony grows out, picking up a single clone to extract plasmid, and storing the pET-Apd plasmid with correct sequence at-20 ℃ for later use.
(3) Expression of adhesin proteins
Escherichia coli competent cells BL21(DE3) were transformed with the plasmid pET-Apd and cultured overnight at 37 ℃. Single colonies were picked in 5mL of LB liquid medium and cultured overnight with shaking at 37 ℃. Transferring into 1000mL LB liquid culture medium at a ratio of 1:100, and shake culturing at 37 deg.C to OD600About 0.6, IPTG was then added to a final concentration of 0.8mM and shake-cultured at 37 ℃ for 4 h. The bacterial solution was centrifuged at 3200g at 4 ℃ for 1min and the bacterial cells were resuspended in 1/10 of the volume of the combined buffer. And (3) crushing the thalli at 4 ℃ by using a low-temperature ultrahigh-pressure cell crusher, repeatedly crushing for 3-5 times, then freezing and centrifuging for 10min at 3200g, and collecting the supernatant for later use.
The IPTG (0.8M): 2g of IPTG was dissolved in 8mL of distilled water to a volume of 10mL, and the solution was sterilized by filtration through a 0.22 μm filter and stored at-20 ℃.
(4) Purification of adhesin proteins
The supernatant of the disrupted cells was harvested, and the supernatant of the disrupted cells was purified with a Ni Sepharose 6 Fast Flow packing (the packing was stored in 20% absolute ethanol) of GE Healthcare to obtain a recombinant adhesin protein rApd whose amino acid sequence is shown in SEQ ID No.2,
the purification process is as follows:
column assembling: covering a cover at the lower end of the purification column, slowly adding 2mL of filler along the wall of the chromatography column to avoid generating bubbles and keep the filler uniformly distributed as much as possible, and standing at 4 ℃ right side for overnight;
balancing: the cap at the lower end of the purification column is opened to allow the liquid in the column to flow out naturally. Adding 10-20 mL of distilled water to wash off ethanol during storage of the filler, adding 20mL of 500mM imidazole buffer solution to wash the nickel ion packed column after the liquid flows out (the operation can be omitted for the new filler), and adding 10-20 mL of combined buffer solution to balance the packed nickel ion packed column after the liquid flows out;
loading: and after the liquid completely flows out, slowly adding 80-100 mL of the crushed thallus supernatant placed on ice into a purification column in a fractional manner.
Washing: and after the protein sample is filled into the column, adding 10-20 mL of binding buffer solution for balancing, and then washing with 20mL of washing buffer solution to remove the foreign protein.
And (3) elution: the target protein sample was washed by adding 10mL of elution buffer slowly in portions, collected in 1.5mL of EP tubes, measured for protein concentration with BCA kit (Biosharp Co.), and stored at-80 ℃. The amino acid sequence of the purified protein is shown as SEQID No. 2.
The binding buffer: NaCl 29.22g, Tris-base 2.42g and imidazole 0.34g, dissolved in 800mL deionized water, adjusted to pH7.4 with concentrated hydrochloric acid, fixed dissolved to 1L, filtered through a 0.22 μm filter, and stored at 4 ℃ for later use.
The washing buffer: NaCl 29.22g, Tris-base 2.42g and imidazole 1.36g, dissolved in 800mL deionized water, adjusted to pH7.4 with concentrated hydrochloric acid, fixed dissolved to 1L, filtered through a 0.22 μm filter, and stored at 4 ℃ for later use.
The elution buffer: NaCl 29.22g, Tris-base 2.42g and imidazole 6.8g are dissolved in 800mL deionized water, the pH value is adjusted to 7.4 by concentrated hydrochloric acid, the solution is fixed to 1L, and the solution is filtered by a 0.22 mu m filter and stored at 4 ℃ for later use.
The 500mM imidazole buffer: weighing 29.22g of NaCl, 2.42g of Tris-base and 34.04g of imidazole, dissolving in 800mL of deionized water, adjusting the pH to 7.4 by using concentrated hydrochloric acid, dissolving to 1L, filtering by using a 0.22 mu m filter, and storing at 4 ℃ for later use
The content of the 20% ethanol: 200mL of absolute ethanol was dissolved in 800mL of deionized water, filtered through a 0.22 μm filter, and stored at 4 ℃ for further use.
Example 3 evaluation of recombinant adhesin protein as coating antigen of Haemophilus parasuis Indirect ELISA antibody detection kit
(1) Expression of three recombinant proteins of haemophilus parasuis
The extracellular regions of 3 outer membrane proteins of Haemophilus parasuis are selected and prokaryotic expression plasmids pET-Ag2, pET-Ag3 and pET-Apd are constructed. Coli BL21(DE3) was transformed with 3 plasmids and induced for different times at different temperatures and different concentrations of IPTG to determine the optimal conditions for soluble expression of the target protein. The result shows that the optimal expression condition of rAg2 (recombiant Ag2) protein is 16 ℃, and 0.2mM IPTG induces for 12 h; rAg3 (recombiant Ag3) protein was induced at 16 ℃ for 12h with 0.2mM IPTG; the optimal expression conditions for rApd (recombiant Apd) protein were 37 ℃ and 0.8mM IPTG induction for 4h (FIG. 1).
(2) Purification of three recombinant proteins of haemophilus parasuis
And (3) crushing the induced escherichia coli by using a low-temperature ultrahigh-pressure cell crusher, centrifuging to take supernatant, purifying target protein by using nickel column affinity chromatography, and eluting the protein with the concentration of 5 mM-300 mM of imidazole respectively. Finally, rAg2 washing buffer containing 50mM imidazole and elution buffer containing 150mM imidazole; the Ag3 wash buffer contained 20mM imidazole and the elution buffer contained 150mM imidazole; the rApd wash buffer contained 20mM imidazole and the elution buffer contained 100mM imidazole. After obtaining the purified protein, the protein concentration of rAg2 was 706. mu.g/mL, the protein concentration of rAg3 was 325. mu.g/mL, and the protein concentration of rApd was 450. mu.g/mL, as determined by BCA protein concentration assay kit, and the purified protein was subjected to SDS-PAGE (FIG. 2).
(3) Three recombinant proteins for detecting Haemophilus parasuis negative positive serum
The three recombinant proteins expressed and purified are diluted to 1 microgram/mL coated enzyme label plate, 4 parts of negative and positive pig serum of haemophilus parasuis are diluted by 1:100 respectively, and indirect ELISA is carried out according to a conventional procedure. The results show that negative serum OD is present when the rApd protein is coated630The mean value was 0.297, positive serum OD630The average value was 2.201 (P)<0.001), the difference between the two is extremely obvious; while OD of negative and positive sera after rAg2 and rAg3 protein coating630The values were all scattered within the range of 1.0 to 2.0, with no clustering (FIG. 3). Therefore, the rApd protein is selected as the coating antigen of the haemophilus parasuis antibody detection kit.
(4) Reactogenicity of recombinant adhesin proteins
Escherichia coli competent cells BL21(DE3) were transformed with pET-Apd, and Western blot was performed using murine His monoclonal antibody and Haemophilus parasuis negative positive pig serum, and the recombinant adhesin protein obtained after induction and purification. Since rApd fused a His tag when expressed in E.coli, a band was observed at 85kDa in the case of detection using His-monoclonal antibody, and a band was observed at 85kDa in positive serum of Haemophilus parasuis, whereas no band was observed in the extract after BL21(DE3) transformation with empty vector (FIG. 4). The result shows that the rApd expressed and purified can react with the porcine antibody of haemophilus parasuis, and the good reactogenicity of the rApd is proved.
(5) Localization of adhesin proteins in haemophilus parasuis
1000mL of haemophilus parasuis logarithmic phase late culture bacterial liquid, centrifuging for 15min at 4 ℃ of 3200g, and discarding the supernatant. The bacterial pellet was resuspended in 60mL of 50mM Tis-HCl (pH7.2), 300. mu.l of PMSF (10mg/mL) as a protease inhibitor was added, and the pellet was sonicated for 25 seconds each at 1min intervals. Until the bacterial fluid becomes clear. Centrifuging at 3200g for 15min, collecting supernatant and 0.1MNa pre-cooled on ice2CO3(pH11) was mixed at a ratio of 1:100 and stirred at 4 ℃ for 1 hour. The solution was centrifuged at 15000g at 4 ℃ for 1h and the precipitate was dissolved in 1mL TE to give the outer membrane protein. 1000mL of Haemophilus parasuis logarithmic phase late phase culture solution, centrifuging at 4 ℃ of 3200g for 30min, collecting supernatant, and filtering with a 0.22 μm filter. To the filtrate was added an equal volume of saturated (NH)4)2SO4Stirring and salting out at 4 ℃ overnight, centrifuging 3200g for 15min, and dissolving the precipitate with TE buffer solution to obtain the secreted protein. Western blot detection was performed with a monoclonal antibody to Apd protein. The results showed that rApd showed a detection band at about 85kD, and that the whole bacterial protein and the outer membrane protein of Haemophilus parasuis showed detection bands of the same size, while the secreted protein did not, indicating that Apd protein is located on the outer membrane of Haemophilus parasuis (FIG. 5).
(6) Antiserum Western blot of recombinant adhesin protein for detecting 15 serotype haemophilus parasuis
Antiserum was prepared by immunizing 4 BALB/c mice with the purified rApd protein. Serum was isolated after three immunizations and titer was measured on an rApd-coated ELISA plate, and serum titer reached 1:204800 for all mice (FIG. 6). Cultures of the 15 serotype standard and isolate CF7066 were subjected to SDS-PAGE followed by membrane transfer and immunoblotting with mouse serum antiserum to the rApd protein, resulting in the appearance of an approximately 85kDa band for all strains, whereas no band was detected for the negative control serum (fig. 7). As can be seen, in the 15 serotype standard strains of HPS, there are antigenic components that can react with the rApd antiserum, indicating that rApd as a diagnostic antigen can be used to detect antibodies of 15 serotypes of Haemophilus parasuis.
(7) Western blot detection of recombinant adhesin protein by 15 serotype haemophilus parasuis antiserum
Preparing 15 serotype standard strains and isolates of haemophilus parasuis CF7066 and BALB/c mouse antiserum of porcine pathogenic escherichia coli, infectious actinobacillus pleuropneumoniae, pasteurella multocida, streptococcus suis and bordetella bronchiseptica. The preparation method comprises the following steps: the cells were spread evenly on TSA plates and cultured overnight, washed with PBS (pH7.4) and the cell content was adjusted to 1010CFU/mL, then emulsified with Freund's adjuvant in the same volume; each mouse was immunized with 300. mu.L (1.5X 10)9CFU/mL), the immunization mode is subcutaneous multipoint injection of the neck and the back; freund's complete adjuvant was used for the first immunization, followed by Freund's incomplete adjuvant. Serum was separated 5 days after the three-immunization and detected by Western blot detection rApd. Except for the antisera of type 6 and type 14, the antisera of the 13 serotype standard and isolate CF7066 reacted with rApd, whereas the antisera of porcine escherichia coli, infectious actinobacillus pleuropneumoniae, streptococcus suis, bordetella bronchiseptica did not react with rApd (fig. 8). The results confirm that the adhesin protein of the haemophilus parasuis has strong immunogenicity, can stimulate animal bodies to produce detectable antibodies, and is relatively conserved in different serotypes of haemophilus parasuis. Therefore, the antibody detection method established by using the antibody as a diagnostic antigen is not limited by serotype, and can not generate cross reaction with other related bacterial pathogens.
Example 4 selection of Components and amounts of kit for detecting Haemophilus parasuis Indirect ELISA antibody and determination of reaction conditions
(1) Determination of antigen coating concentration and enzyme-labeled secondary antibody working concentration
rApd was diluted to 2. mu.g/mL, 1. mu.g/mL, 0.5. mu.g/mL, 0.25. mu.g/mL, 0.125. mu.g/mL with the coating solution, and the enzyme-labeled secondary antibody was diluted to 1:5000, 1:10000, 1:15000, 1:20000 times with the sample diluent. Of Haemophilus parasuisPositive and negative sera were diluted 1:100 with sample diluent. The results showed that positive and negative serum OD were obtained when the antigen coating concentration was 0.5. mu.g/mL and the secondary antibody dilution was 1:15000630The ratio (P/N) of (A) was the largest, and thus 0.5. mu.g/mL and 1:15000 were used as the antigen optimum coating concentration and the secondary antibody optimum dilution (Table 1).
TABLE 1 determination of optimal antigen coating concentration and enzyme-labeled secondary antibody working concentration
(2) Determination of antigen coating conditions
Coating the enzyme label plate with an antigen concentration of 0.5 mu g/mL, wherein the coating conditions are as follows: coating at 4 ℃ overnight, coating at 37 ℃ for 1h, then coating at 4 ℃ overnight, coating at 37 ℃ for 2h, then coating at 4 ℃ overnight, and coating at 37 ℃ for 2 h. The results showed that the overnight P/N value at 4 ℃ was 12.097, which is higher than that of the other coating conditions, so that the optimal antigen coating condition was 4 ℃ overnight (Table 2).
TABLE 2 determination of optimal conditions for antigen coating
(3) Determination of serum dilution factor and reaction time
Diluting the positive and negative serum by 1:50, 1:100, 1:200 and 1:400 times, adding 100 μ L into the coated enzyme label plate, and performing indirect ELISA in 37 deg.C incubator for 30min, 45min, 60min and 75min respectively. As a result, the P/N value was the largest when the serum was diluted 1:200 times and the reaction time was 45min, and therefore the optimal dilution ratio of the serum to be tested was 1:200 and the optimal reaction time was 45min (Table 3).
TABLE 3 determination of optimal dilution times and reaction times for sera
(4) Selection of confining liquids
After coating, the protein is blocked by different blocking liquids. The confining liquid is respectively as follows: the PBS buffer contained 0.1g/L skim milk, 0.5g/L skim milk, 0.05g/L BSA, 0.2g/L BSA. As a result, it was found that the P/N value was the largest when the blocking solution contained 5g/L of skim milk, and therefore the most preferable blocking solution was PBS buffer (pH7.4) containing 5g/L of skim milk (Table 4).
TABLE 4 determination of optimal blocking solution
(5) Determination of the closing time
3 different closure times were set: sealing at 37 ℃ for 1h, sealing at 37 ℃ for 2h, and sealing at 37 ℃ for 3 h. Detecting OD per closure time630As a result, it was found that the P/N value was the largest when the blocking time was 2 hours, and the optimum blocking time was 2 hours (Table 5).
TABLE 5 determination of optimal seal time
(6) Determination of enzyme-labeled Secondary antibody action time
By adopting the optimized ELISA reaction conditions, 100 mu L of goat anti-pig secondary antibody is added into each hole, and the mixture is respectively acted for 30min, 45min, 60min and 75min in a 37 ℃ incubator. The results showed that the secondary antibody had the greatest P/N value at 30min, so the optimal action time was 30min (Table 6).
TABLE 6 determination of optimal action time of enzyme-labeled secondary antibody
(7) Determination of the development time of a substrate
And (3) adopting the optimized ELISA reaction conditions, adding the substrate solution A and the substrate solution B, and then performing color development at room temperature in a dark place for 5min, 10min, 15min and 20min respectively. The results showed that the P/N value was the greatest when the color was developed for 15min, so the optimal color development time for the substrate was 15min (Table 7).
TABLE 7 determination of optimal coloration time of the substrate
(8) Detection of negative and positive pig serum after optimization of ELISA reaction conditions
And (3) detecting 15 parts of each of the Haemophilus parasuis negative and positive pig serum by using the optimized rApd coating concentration, the sealing solution and the sealing time, the dilution multiple of the serum to be detected, the dilution concentration and the action time of the enzyme-labeled secondary antibody and the substrate development time. The results show that the conditions are optimized
The background of the ELISA test results was significantly reduced. Of positive seraFrom 2.514 to
1.438, negative serumThe standard deviation is reduced to 0.14 from 1.400 (figure 9), which shows that the optimization of the ELISA component dosage and the reaction condition effectively improves the detection effect of the kit
Example 5 determination of Positive threshold value of Indirect ELISA antibody detection kit for Haemophilus parasuis
(1) Formula for determining critical value
The indirect ELISA positive determination standard generally adopts the average OD value of a large number of negative samples plus one or more times of the standard deviation of the OD values of the negative samples, namely therefore, after various test conditions of indirect ELISA operation are fixed, the positive critical value is determined in three steps, namely n value in ① critical value calculation formula, more reliable values when the number of the serum is more than the standard deviation of ① plurality of negative samples, and negative control value in ③ actual detection (Wu BaoCheng, 1994).
(2) Determination of the value of n in the threshold value
The method for measuring the n-value is as follows, with reference to the method used by Wu Baocheng et al (1994). Taking positive and negative serums of haemophilus parasuis, diluting to 1:204800 from 1:100 in a multiple ratio, sequentially adding an rApd coated enzyme label plate, and adding 8 holes at each dilution to determine OD of each hole630The OD of the positive and negative serum was calculated for each dilution630And the corresponding t value (table 8). The statistical analysis shows that when the dilution is 1:12800, t is 2.571 > 2.145{ t ═ t(0.05,14)Of samples of negative and positive seraThe difference is obvious; as the dilution continues to increase in size,yang is less thanNegative, indicating that this method has been unable to distinguish between the yin-yang sera. It can be seen that at a dilution of 1:12800, the t value 2.571 is the value of n in the threshold. The result also shows that when the serum to be detected is diluted at 1:12800, the method can detect the yin-yang serum and shows that the serum is sensitiveThe sensitivity is high.
TABLE 8 determination of multiple of standard deviation in threshold values
(3) Method for screening haemophilus parasuis negative serum
And (3) crushing and centrifuging the cultured haemophilus parasuis and the thallus, measuring the bacterial load and the protein concentration, diluting the obtained product in a multiple ratio, coating an enzyme label plate, and detecting one portion of each of the haemophilus parasuis negative and positive pig serum. The results showed that when the supernatant after disruption was used as the coating antigen, negative and positive serum OD630The values are all higher, and the P/N value is between 1 and 2 (figure 9); while when the whole bacteria is used as the coating antigen, the negative and positive serum OD630The difference in values increases significantly, with P/N values greater than 2. Especially when the coating concentration of the bacteria is 0.5X 108The P/N value is 2.47 and the positive serum OD is at CFU/mL630Value 1.153, negative serum OD630The value was 0.467 (fig. 10).
(4) Determination of negative serum standard deviation in cutoff values
By 0.5X 108CFU/mL haemophilus parasuis thallus suspension coating ELISA plate, screening haemophilus parasuis negative serum, OD from 350 parts of clinical suckling piglet, nursery pig, fattening pig and sow serum by indirect ELISA630A value less than 0.467 is judged as negative serum. The result was 40 negative, 4 for suckling piglets, 23 for nursery pigs, and 13 for fattening pigs. The ELISA antibody detection method of the present invention was used to detect 40 sera
Detection, OD630Average value of (2)It was 0.189 and the Standard Deviation (SD) was 0.118.
TABLE 9 results of detecting 40 portions of Haemophilus parasuis negative serum
(5) Determination of Positive Critical value
According to the n value of 2.571, the OD of 40 negative serum samples630 Is 0.189, the Standard Deviation (SD) is 0.118, andavailable threshold value of 0.492, i.e. when OD630When the content is more than or equal to 0.492, the serum sample is positive; when OD is reached630<At 0.492, the serum sample was negative.
Considering the batch difference in the preparation process of the ELISA kit and the personal operation error in the use process, under the premise of strictly preparing and controlling the negative and positive control serum, the positive critical value is judged to be positive according to the S/N value (0.492/0.189-2.60), namely when the S/N value of the serum to be detected is more than or equal to 2.60; S/N<2.6, the result is judged to be negative. S represents the OD of the serum to be tested630Value, N represents the negative control serum OD630Value, test was established as negative and positive control serum OD630The difference is greater than or equal to 0.5.
Example 6 composition and preparation of Indirect ELISA antibody detection kit for Haemophilus parasuis
(1) Preparation of recombinant adhesin protein Apd coated ELISA plate
Diluting the purified rApd protein with a coating solution to a concentration of 0.5 mu g/mL, adding 100 mu L of the protein into an ELISA plate per hole, and keeping the temperature in a refrigerator at 4 ℃ overnight; discarding the coating solution, adding 200 μ L of washing solution into each hole, standing for 5min, discarding the supernatant, and washing for 3 times;
then adding 200 mu L of sealing liquid into each hole, and acting for 2 hours at 37 ℃ in an incubator; removing the confining liquid, adding 200 μ L of washing liquid into each well, standing for 5min, removing the supernatant, drying, and washing for 3 times; freeze drying, and vacuum preserving at low temperature.
The coating liquid comprises: carbonate buffer (pH9.6), Na2CO31.59g、NaHCO32.93g, adding a proper amount of deionized water for dissolution, adjusting the pH to 9.6 by hydrochloric acid, fixing the volume to 1L, sterilizing at high pressure and storing at 4 ℃ for later use;
the washing solution comprises: 50. mu.L of Tween-20 was added to 100mL of PBS buffer (pH7.4);
the sealing liquid is prepared by the following steps: PBS buffer (pH7.4) containing 5g/L skim milk.
(2) Kit composition for detecting adhesin protein indirect ELISA antibody
The kit comprises 2 blocks of an adhesin-coated 96-hole ELISA detection plate, 1 bottle (50 mL/bottle) of sample diluent, 1 tube (1.5 mL/tube) of negative and positive control serum, 1 bottle (30 mL/bottle) of 20-time concentrated washing solution, 1 bottle (20 mL/bottle) of enzyme-labeled secondary antibody, 1 bottle (10 mL/bottle) of developing solution A, developing solution B and stop solution.
The sample diluent is: 50mL of PBS buffer solution (pH7.4), 0.25g of bovine serum albumin and 0.5 μ L of Tween-2025;
the positive control serum: the preparation method comprises the following steps: immunizing 1-month-old healthy piglet with Haemophilus parasuis twice, collecting blood serum two weeks after two-time immunization, and detecting OD630Taking 4 parts of serum with the value of 1.00-1.20, mixing, and diluting with a sample diluent at a ratio of 1:200 to serve as positive control serum;
the negative control serum: detecting OD of healthy pig serum raised under the same condition during positive control serum preparation630Mixing 4 parts of serum with a value of 0.15-0.25, and diluting with sample diluent at a ratio of 1:200 to obtain negative control serum;
the 20-fold concentrated washing solution: 160.00g of NaCl, 4.00g of KCl and Na2HPO4·12H2O 72.60g,KH2PO44.80g of the extract is dissolved in 900mL of deionized water, the pH value is adjusted to 7.4 by concentrated hydrochloric acid, 10mL of Tween-20 is added, the volume is fixed to 1L, and the extract is filtered, sterilized and stored at room temperature;
the enzyme-labeled secondary antibody: horse radish peroxidase-labeled goat anti-pig secondary antibody purchased from Wuhan Ante & Tejie biotechnology Limited (imported subpackaging) and diluted by sample diluent at a ratio of 1: 15000;
the color developing liquid A: na (Na)2HPO4·12H2Adding 800ml of deionized water into 14.60g of O, 9.33g of citric acid and 2ml of 30% hydrogen peroxide for dissolving, adjusting the pH value to 5.0-5.4, and fixing the volume to 1000 ml;
the color developing liquid B: 20.00mg of Tetramethylbenzidine (TMB) and 10ml of absolute ethyl alcohol, adding deionized water for dissolving and fixing the volume to 1000 ml;
the stop solution is as follows: to 10mL of deionized water was added 25. mu.L of hydrofluoric acid.
(3) Method of using kit
Diluting a serum sample to be detected by a sample diluent at a ratio of 1:200, taking 100 mu L of each sample, adding the sample into an enzyme label plate, and simultaneously taking 100 mu L of negative and positive control serum and adding the negative and positive control serum into the enzyme label plate; performing incubator at 37 deg.C for 45min, diluting 20 times of concentrated washing solution with deionized water at a ratio of 1:19, adding 200 μ L per well, standing for 5min, discarding, drying, and washing for 3 times;
adding 100 μ L of enzyme-labeled secondary antibody into each well, reacting at 37 deg.C for 30min, discarding, adding 200 μ L of washing solution into each well, standing for 5min, discarding, drying, and washing for 3 times;
adding 50 mu L of substrate solution A into each hole, adding 50 mu L of substrate solution B, uniformly mixing, keeping out of the sun at room temperature for 15min, developing, adding 50 mu L of stop solution, and measuring the OD value with the wavelength of 630nm on an enzyme-linked immunosorbent assay instrument within 10 min;
and (4) judging a result: when the S/N of the serum to be detected is more than or equal to 2.60, the serum is judged to be positive; S/N<2.6, the result is judged to be negative. S represents the OD of the serum to be tested630Value, N represents the negative control serum OD630Value, the condition for the test to be established is the negative and positive control serum OD630The difference is greater than or equal to 0.5.
The pig serum to be detected is as follows: porcine venous blood serum was isolated.
Example 7 reproducibility of the Haemophilus parasuis Indirect ELISA antibody detection kit
And respectively carrying out batch repeatability experiments on 4 parts of positive serum and 4 parts of negative serum of the haemophilus parasuis by using the enzyme label plates coated in the same batch. Repeating the detection for 4 times, wherein the variation coefficient is between 1.9 and 9.5 percent; the ELISA plates coated in different batches are used for carrying out batch-to-batch repeatability experiments on the same 8 parts of serum, and the variation coefficient of the ELISA plates is between 1.4 and 9.4 percent (shown in a table 10), which shows that the ELISA detection kit has good repeatability.
TABLE 10 Intra-and inter-batch repeat tests
Example 8 application of Haemophilus parasuis Indirect ELISA antibody detection kit
(1) Detection of vaccine immunity and attenuated pig serum
The ELISA kit is used for detecting pig serum immunized by a haemophilus parasuis vaccine and infected by a low virulent strain, wherein 15 parts of the vaccine immune serum, 4 parts of low virulent strain infected serum and 20 parts of PBS control serum are used as positive judgment standards, and S/N is more than or equal to 2.60. The results showed that 93% (14/15) of the vaccine immunization groups were positive, 100% (4/4) of the attenuated strain A infection group was positive, and 75% (15/20) of the PBS control group was negative (FIG. 12). Notably, the PBS control group tested positive for antibodies with 5 sera, which may be due to endogenous or cross-infection of pigs during the test, since haemophilus parasuis is a common bacterium and the animal test lasted for 6 weeks. However, the results of the challenge test showed that there were 8 cases of the PBS control group showing no clinical symptoms, suggesting that PBS pigs may have a substantial infection and antibody production. In sum, the results show that the kit can detect the serum antibody of the haemophilus parasuis vaccine after immunization and live bacteria infection, and can be applied to the evaluation of the haemophilus parasuis vaccine immune protection effect and the antibody detection after pathogen infection.
(2) Evaluation of antibody growth and elimination rules after vaccine immunization and attenuated infection
The ELISA antibody detection kit is used for carrying out continuous antibody detection on experimental infected pigs. 16 piglets of one month old are divided into 4 groups, 4 piglets in each group are immunized/infected twice at intervals of two weeks, inactivated vaccine A immunization and gene deletion strain B and C infection are respectively carried out, and S/N is more than or equal to 2.60 and is taken as a positive judgment standard. The results show that the appearance of the ELISA antibodies of the low virulent strains B and C turns positive one week after infection, and the ELISA antibodies continuously rise two weeks later; the vaccine immunization group turned positive for a week of secondary immunization with a significant increase in antibody. The antibody levels of the vaccine immunization and the attenuated strain-infected group were the same two weeks after immunization, while the antibody detection of the PBS control group continued to be negative (fig. 13). Therefore, the kit can also be used for evaluating the antibody generation rule after vaccine immunization and pathogen infection.
(3) Detection of clinical pig serum
The ELISA antibody kit is used for detecting 222 parts of serum collected by 3 pig farms, including suckling piglet, nursery pig, fattening pig and sow serum. The result shows that the positive detection rate is 12 percent of suckling piglets, 16 percent of nursery pigs, 36 percent of fattening pigs, 68 percent of sows and 35 percent of total positive detection rate in sequence. By 0.5X 108The CFU/mL haemophilus parasuis coated ELISA plate was tested, and the positive rates detected were 84% for suckling piglets, 74% for nursery pigs, 86% for fattening pigs, 100% for sows and 86% for total positive rate (Table 11). Both tests showed that the antibody positive rate increased with the increase of the day-old pig. However, when the bacterial cells were used as the coating antigen, the positive rate was significantly high. May produce antibodies with other bacteria due to the kinds and amounts of the bacterial antigen componentsCross-reactivity is relevant, and such cross-reactivity can be avoided by using recombinant adhesin Apd protein as the coating antigen. More importantly, the total positive rate detected by using the kit in 222 serum samples is 35%, which is basically consistent with the separation rate of the haemophilus parasuis in a swinery of 30%, and can reflect the infection and epidemic trend of the haemophilus parasuis more truly.
TABLE 11 kit and ELISA for detection of clinical sera by bacteria
Other parts not described in detail are prior art. Although the above embodiments have been described in detail, they are only a part of the embodiments of the present invention, rather than all embodiments, and other embodiments can be obtained without inventive step according to the embodiments, and the embodiments are within the scope of the present invention.
Sequence listing
<110> university of agriculture in Huazhong
<120> adhesin protein Apd and application thereof in preparation of indirect ELISA antibody detection kit for haemophilus parasuis
<160>2
<170>SIPOSequenceListing 1.0
<210>1
<211>1577
<212>DNA
<213> Haemophilus parasuis (Haemophilus parasuis)
<400>1
cggaattcgg aaacttatat tgttactggt gaaaataaca atgtgcgcgg cgaacaattc 60
caacgtttac ttaaccaagc caaagatggc gatacaattc gcttagacgg agatactcaa 120
ttattgcgtg gaagtggttt tttcaatgtt gataaacaag taacaattga tggacaagga 180
aatcgcttac accttgaagg ttataatttg tccttaggac aagatgttac tttttcgaat 240
gtaaatttat ccttaaaacc tagtcgagat ttaaacaata tttttggttc tggatttaat 300
aatttaaaag cagcatctac ctatattgtg accaatggaa ataaattgat cttggataat 360
gttagaacga atgttaatgg tgaacctgca gatactcgcc caatgatttt acttggaaat 420
attgatccaa caaaaaataa taatggacac gatgctcttg tagtgacaaa tgctcaccca 480
acagaaacaa tattatcttc agtggttgtt ataggcaata acaattcaaa tactgacacc 540
ccagtaacga ttagtttagg ggaaaatgtc agctttgtta atcaggtaat atttgagaga 600
gaaggagaag aggatatata tagtggtgcg gtgtatctag ctggaatgaa taatgatcaa 660
gaacataaca gagctattaa tttctctagt tcatcaaatg ctatcactaa aatttatacg 720
ggagaagcta caaatgtttc tgttacgtta aataacatca atcctgaaac tgctatcact 780
ttacaagatg ttaaagattt aacattaaat aatagccgta ttactttgga taagaattta 840
tctgtttcag aaaccttaac tctgaataat caatccgcaa tcactacagt ggcgagtaaa 900
gatgcttttg gtgacatcgc taagactagt ttgatgttaa ataatatcca taccaatggt 960
aataatagta atatcactat cgttcgggac aatgctcttt tgattaatgg taatattact 1020
ggtgaattga ctattaatac agaagataaa gataataacg ttagtcttcc taatggcagc 1080
actttagtag gagaaaatgg cagctatgtt gtgaagctaa aaacagaagt aactcaacct 1140
gtatcagaaa atacaactac tgacagcagt aatactgatg taacccctgc taaacctacg 1200
gatagcacac cagcaacaac aggcgaacaa actggttcgt cagatacaac atcaccaaca 1260
aatacagctg caactagcaa tgaaactaca ccgcctgcta caacgggaga tacagcgact 1320
aacagcagta atactgatgt accccctgct acacctacgg atagcacacc agcaacaaca 1380
ggcgaacaaa ctggttcgtc agatataaca tcgccaacag atacagctca aacagacgat 1440
caagcggagg cttctagctc tgacactgca acatctacac cagcacaacc aacgggcgat 1500
gtagcttcaa caagtgaaca agcgacaacg tcgagtacat ctacaaacca caataaaatc 1560
acaatcaccc tcgaggg 1577
<210>2
<211>557
<212>PRT
<213> Haemophilus parasuis (Haemophilus parasuis)
<400>2
Met Asp Ile Gly Ile Asn Ser Asp Pro Asn Ser Glu Thr Tyr Ile Val
1 5 10 15
Thr Gly Glu Asn Asn Asn Val Arg Gly Glu Gln Phe Gln Arg Leu Leu
20 25 30
Asn Gln Ala Lys Asp Gly Asp Thr Ile Arg Leu Asp Gly Asp Thr Gln
35 40 45
Leu Leu Arg Gly Ser Gly Phe Phe Asn Val Asp Lys Gln Val Thr Ile
50 55 60
Asp Gly Gln Gly Asn Arg Leu His Leu Glu Gly Tyr Asn Leu Ser Leu
65 70 75 80
Gly Gln Asp Val Thr Phe Ser Asn Val Asn Leu Ser Leu Lys Pro Ser
85 90 95
Arg Asp Leu Asn Asn Ile Phe Gly Ser Gly Phe Asn Asn Leu Lys Ala
100 105 110
Ala Ser Thr Tyr Ile Val Thr Asn Gly Asn Lys Leu Ile Leu Asp Asn
115120 125
Val Arg Thr Asn Val Asn Gly Glu Pro Ala Asp Thr Arg Pro Met Ile
130 135 140
Leu Leu Gly Asn Ile Asp Pro Thr Lys Asn Asn Asn Gly His Asp Ala
145 150 155 160
Leu Val Val Thr Asn Ala His Pro Thr Glu Thr Ile Leu Ser Ser Val
165 170 175
Val Val Ile Gly Asn Asn Asn Ser Asn Thr Asp Thr Pro Val Thr Ile
180 185 190
Ser Leu Gly Glu Asn Val Ser Phe Val Asn Gln Val Ile Phe Glu Arg
195 200 205
Glu Gly Glu Glu Asp Ile Tyr Ser Gly Ala Val Tyr Leu Ala Gly Met
210 215 220
Asn Asn Asp Gln Glu His Asn Arg Ala Ile Asn Phe Ser Ser Ser Ser
225 230 235 240
Asn Ala Ile Thr Lys Ile Tyr Thr Gly Glu Ala Thr Asn Val Ser Val
245 250 255
Thr Leu Asn Asn Ile Asn Pro Glu Thr Ala Ile Thr Leu Gln Asp Val
260 265 270
Lys Asp Leu Thr Leu Asn Asn Ser Arg Ile Thr Leu Asp Lys Asn Leu
275 280 285
Ser Val Ser Glu Thr Leu Thr Leu Asn Asn Gln Ser Ala Ile Thr Thr
290 295 300
Val Ala Ser Lys Asp Ala Phe Gly Asp Ile Ala Lys Thr Ser Leu Met
305 310 315 320
Leu Asn Asn Ile His Thr Asn Gly Asn Asn Ser Asn Ile Thr Ile Val
325 330 335
Arg Asp Asn Ala Leu Leu Ile Asn Gly Asn Ile Thr Gly Glu Leu Thr
340 345 350
Ile Asn Thr Glu Asp Lys Asp Asn Asn Val Ser Leu Pro Asn Gly Ser
355 360 365
Thr Leu Val Gly Glu Asn Gly Ser Tyr Val Val Lys Leu Lys Thr Glu
370 375 380
Val Thr Gln Pro Val Ser Glu Asn Thr Thr Thr Asp Ser Ser Asn Thr
385 390 395 400
Asp Val Thr Pro Ala Lys Pro ThrAsp Ser Thr Pro Ala Thr Thr Gly
405 410 415
Glu Gln Thr Gly Ser Ser Asp Thr Thr Ser Pro Thr Asn Thr Ala Ala
420 425 430
Thr Ser Asn Glu Thr Thr Pro Pro Ala Thr Thr Gly Asp Thr Ala Thr
435 440 445
Asn Ser Ser Asn Thr Asp Val Pro Pro Ala Thr Pro Thr Asp Ser Thr
450 455 460
Pro Ala Thr Thr Gly Glu Gln Thr Gly Ser Ser Asp Ile Thr Ser Pro
465 470 475 480
Thr Asp Thr Ala Gln Thr Asp Asp Gln Ala Glu Ala Ser Ser Ser Asp
485 490 495
Thr Ala Thr Ser Thr Pro Ala Gln Pro Thr Gly Asp Val Ala Ser Thr
500 505 510
Ser Glu Gln Ala Thr Thr Ser Ser Thr Ser Thr Asn His Asn Lys Ile
515 520 525
Thr Ile Thr Leu Glu Ile Lys Arg Ala Ser Gln Pro Glu Leu Ala Pro
530 535 540
Glu Asp Pro Glu Asp Val Glu His His His His His His
545 550 555
Claims (10)
1. An adhesin protein Apd, whose amino acid sequence is characterized by:
(1) a protein consisting of an amino acid sequence shown in SEQ ID No. 2; or
(2) An amino acid sequence which has 90-100% homology with the amino acid sequence defined by the sequence SEQ ID No.2 and encodes the protein with the same function; or
(3) And (2) the protein which is derived from the protein (1) and has the same activity and is added with, deleted from or substituted for one or more amino acids in the amino acid sequence shown in SEQ ID No. 2.
2. Encodes the adhesin gene apd of claim 1.
3. The gene of claim 2, wherein the nucleotide sequence is shown in SEQ ID No. 1.
4. Primer pair for obtaining the adhesin gene apd of claim 3, characterized in that: the primer pair is as follows:
P1,5’-CGGAATTCGGAAACTTATATTGTTACTGGTGAA-3’,
P2,5’-CCCTCGAGGGTGATTGTGATTTTATTGTGGT-3’。
5. a recombinant plasmid pET-Apd, characterized by: the recombinant expression vector is an expression vector containing the adhesin gene apd of claim 3, wherein the expression vector is pET-25 b.
6. A host cell comprising the recombinant expression vector of claim 5, wherein: the host cell is Escherichia coli BL21(DE 3).
7. A method of producing recombinant adhesin protein Apd using the host cell of claim 6: the method is characterized in that: the method comprises the following steps:
(1) culturing escherichia coli competent cells BL21(DE3) containing recombinant plasmid pET-Apd overnight, centrifuging culture bacterial liquid, and resuspending a precipitate by using a buffer solution to obtain suspension bacterial liquid;
(2) and (3) carrying out thallus crushing on the suspension liquid at a low temperature, centrifugally collecting a supernatant, and purifying the supernatant to obtain the recombinant adhesin protein rApd.
8. An indirect ELISA antibody detection kit for haemophilus parasuis is characterized in that: the adhesin-coated elisa plate prepared in claim 7, sample diluent, negative and positive control serum, 20-fold concentrated washing solution, elisa secondary antibody, developing solution A, developing solution B, stop solution; wherein,
the sample diluent is: pH7.4 is 50mL of PBS buffer solution, 0.25g of bovine serum albumin and Tween-2025 mu L;
the positive control serum: the preparation method comprises the following steps: immunizing 1-month-old healthy piglet with Haemophilus parasuis twice, collecting blood serum two weeks after two-time immunization, and detecting OD630Taking 4 parts of serum with the value of 1.00-1.20, mixing, and diluting with a sample diluent at a ratio of 1:200 to serve as positive control serum;
the negative control serum: detecting OD of serum of healthy pig fed under the same condition during preparation of positive control serum630Taking 4 parts of serum with the value of 0.15-0.25, mixing, and diluting with a sample diluent at a ratio of 1:200 to serve as negative control serum;
the 20-fold concentrated washing solution: 160.00g of NaCl, 4.00g of KCl and Na2HPO4·12H2O 72.60g,KH2PO44.80g of the extract is dissolved in 900mL of deionized water, the pH value is adjusted to 7.4 by concentrated hydrochloric acid, 10mL of Tween-20 is added, the volume is fixed to 1L, and the extract is filtered, sterilized and stored at room temperature;
the enzyme-labeled secondary antibody: horse radish peroxidase-labeled goat anti-pig secondary antibody purchased from Wuhan Antagile biotechnology Limited and diluted by sample diluent at a ratio of 1: 15000;
the color developing liquid A: na (Na)2HPO4·12H2Adding 800ml of deionized water into 14.60g of O, 9.33g of citric acid and 2ml of 30% hydrogen peroxide for dissolving, adjusting the pH value to 5.0-5.4, and fixing the volume to 1000 ml;
the color developing liquid B: 20.00mg of tetramethyl benzidine and 10.00ml of absolute ethyl alcohol, adding deionized water for dissolving and fixing the volume to 1000 ml;
the stop solution is as follows: to 10mL of deionized water was added 25. mu.L of hydrofluoric acid.
9. The indirect Haemophilus parasuis ELISA antibody detection kit of claim 8, wherein:
the adhesin protein coated ELISA plate: the preparation method comprises the following steps: taking the purified rApd protein as a coating antigen; taking 0.10M carbonate buffer solution with pH of 9.6 as coating solution; rApd was diluted to 0.50. mu.g/mL and coated overnight at 4 ℃; blocking was performed with 0.05g/mL skim milk in PBS buffer pH7.4 at 37 ℃ for 2 h.
10. A method for detecting Haemophilus parasuis antibodies by using the kit of claim 8, wherein the kit comprises: the method comprises the following steps:
(1) diluting the serum to be detected by sample diluent at a ratio of 1:200, adding 100 mu L of each sample into an enzyme label plate, and simultaneously adding 100 mu L of negative and positive control serum into the enzyme label plate; performing incubator at 37 deg.C for 45min, diluting 20 times of concentrated washing solution with deionized water at a ratio of 1:19, adding 200 μ L per well, standing for 5min, discarding, drying, and washing for 3 times;
(2) adding 100 μ L of enzyme-labeled secondary antibody into each well, reacting at 37 deg.C for 30min, discarding, adding 200 μ L of washing solution into each well, standing for 5min, discarding, drying, and washing for 3 times;
(3) adding 50 mu L of substrate solution A into each hole, adding 50 mu L of substrate solution B, uniformly mixing, keeping out of the sun at room temperature for 15min, developing, adding 50 mu L of stop solution, and measuring the OD value with the wavelength of 630nm on an enzyme-linked immunosorbent assay instrument within 10 min;
(4) and (4) judging a result: when the S/N of the serum to be detected is more than or equal to 2.60, the serum is judged to be positive; S/N<2.6, judging the test result to be negative; wherein S represents the OD of the serum to be detected630Value, N represents the negative control serum OD630Value, the condition for the test to be established is the negative and positive control serum OD630The difference value is more than or equal to 0.5, and the serum of the pig to be detected: porcine venous blood serum was isolated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810730559.8A CN109030830B (en) | 2018-07-05 | 2018-07-05 | Adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810730559.8A CN109030830B (en) | 2018-07-05 | 2018-07-05 | Adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109030830A true CN109030830A (en) | 2018-12-18 |
CN109030830B CN109030830B (en) | 2019-09-10 |
Family
ID=64640333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810730559.8A Active CN109030830B (en) | 2018-07-05 | 2018-07-05 | Adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109030830B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110376388A (en) * | 2019-08-16 | 2019-10-25 | 南京农业大学 | A kind of haemophilus parasuis antibody detection method and its kit |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101968490A (en) * | 2010-08-26 | 2011-02-09 | 广东省农业科学院兽医研究所 | Indirect ELISA (Enzyme-Linked Immunosorbent Assay) method and kit for detecting haemophilus parasuis antibodies |
CN104293966A (en) * | 2014-10-23 | 2015-01-21 | 上海交通大学 | Double PCR (polymerase chain reaction) detection method for haemophilus parasuis |
CN106501511A (en) * | 2016-11-10 | 2017-03-15 | 永州职业技术学院 | A kind of indirect ELISA method of restructuring Neu Protein Detection haemophilus parasuises antibody and its test kit |
-
2018
- 2018-07-05 CN CN201810730559.8A patent/CN109030830B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101968490A (en) * | 2010-08-26 | 2011-02-09 | 广东省农业科学院兽医研究所 | Indirect ELISA (Enzyme-Linked Immunosorbent Assay) method and kit for detecting haemophilus parasuis antibodies |
CN104293966A (en) * | 2014-10-23 | 2015-01-21 | 上海交通大学 | Double PCR (polymerase chain reaction) detection method for haemophilus parasuis |
CN106501511A (en) * | 2016-11-10 | 2017-03-15 | 永州职业技术学院 | A kind of indirect ELISA method of restructuring Neu Protein Detection haemophilus parasuises antibody and its test kit |
Non-Patent Citations (2)
Title |
---|
NCBI: "Haemophilus parasuis SH0165,complete genome", 《NCBI》 * |
NCBI: "putative pertactin family virulence factor,outer membrane autotransporter/Type V secretory pathway,adhesion AidA[Glaesserella parasuis SH0165]", 《NCBI》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110376388A (en) * | 2019-08-16 | 2019-10-25 | 南京农业大学 | A kind of haemophilus parasuis antibody detection method and its kit |
CN110376388B (en) * | 2019-08-16 | 2021-10-19 | 南京农业大学 | Haemophilus parasuis antibody detection method and kit thereof |
Also Published As
Publication number | Publication date |
---|---|
CN109030830B (en) | 2019-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108614121B (en) | Bovine viral diarrhea virus E2 protein antigen multi-epitope fusion peptide and preparation and application thereof | |
Zhang et al. | Identification of linear B cell epitope on gB, gC, and gE proteins of porcine pseudorabies virus using monoclonal antibodies | |
CN105061602B (en) | For detecting fusion protein, the preparation method and application of anti-pig enterotoxigenic escherichia coil antibody | |
CN110746495A (en) | Recombinant protein E2 and application thereof | |
CN110642927B (en) | Application of protein in preparation of medicine for preventing cryptococcus pyogenes infection | |
CN111793130B (en) | Haemophilus parasuis CdtB hybridoma cell and application of monoclonal antibody | |
CN109239341B (en) | Indirect ELISA kit for detecting bovine haemolytic mannheimia antibody and application thereof | |
CN111621506B (en) | Mycoplasma bovis secretory protein Mbovp0145 and application thereof | |
CN109030830B (en) | Adhesin albumin A pd and its preparing the application in haemophilus parasuis indirect ELISA antibody assay kit | |
CN110376388B (en) | Haemophilus parasuis antibody detection method and kit thereof | |
CN101303349B (en) | Cysticercosis cellulosae indirect ELISA testing kit and preparation method thereof | |
CN109762052B (en) | Porcine circovirus type 3 Cap recombinant protein and coding gene and application thereof | |
CN110257405B (en) | Mycoplasma bovis alcohol dehydrogenase gene and encoding protein and application thereof | |
CN111978410A (en) | Fusion protein of brucella outer membrane protein OMP25 and periplasmic protein BP26 as well as expression and application thereof | |
WO2013033092A2 (en) | Streptococcus suis pilus antigens | |
CN111537732B (en) | Application of salmonella gallinarum SifA protein in preparation of ELISA antibody detection kit for detecting salmonella gallinarum antibody | |
CN105754951B (en) | Monoclonal antibody of anti-capripoxvirus K3L protein and application thereof | |
CN114839368A (en) | Swine Gata virus indirect ELISA antibody detection method and kit thereof | |
CN110540599B (en) | Klebsiella pneumoniae Elisa detection kit based on Klebsiella pneumoniae surface protein antibody and preparation method thereof | |
CN105754952B (en) | Monoclonal antibody of anti-capripoxvirus K3L protein C terminal and application thereof | |
CN113444157B (en) | Application of mycoplasma hyorhinis outer membrane protein Mhr _0461 in preparation of mycoplasma hyorhinis or antibody detection kit thereof | |
CN110540598B (en) | Haemophilus influenzae Elisa detection kit based on surface protein antibody of haemophilus influenzae and preparation method | |
CN113461791B (en) | Application of mycoplasma hyorhinis outer membrane protein Mhr _0493 in preparation of mycoplasma hyorhinis or antibody detection kit thereof | |
CN114751963B (en) | Protein for detecting foot-and-mouth disease virus antibody and application thereof | |
CN114805501B (en) | Porcine circovirus type 2 antigen composition and application thereof in antigen quantification method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |